Heptares Therapeutics
Develops novel, small-molecule drugs for G-protein-coupled receptors.
Launch date
Market cap
-
Enterprise valuation
€364m (Public information from Apr 2017)
Company register number 06267989
Tokyo Japan (HQ)
Financials
Estimates*
USD | 2016 | 2017 | 2018 | 2019 | 2020 |
---|---|---|---|---|---|
Revenues | - | 44.0m | 9.9m | 88.0m | 77.0m |
% growth | - | - | (78 %) | 789 % | (13 %) |
EBITDA | 99.0m | (22.0m) | (44.0m) | 33.0m | 22.0m |
% EBITDA margin | - | (50 %) | (444 %) | 38 % | 29 % |
Profit | - | 44.0m | 44.0m | - | 33.0m |
% profit margin | - | 100 % | 444 % | - | 43 % |
Date | Investors | Amount | Round |
---|---|---|---|
* | N/A | Spinout | |
N/A | Seed | ||
£21.0m | Series A | ||
$21.0m | Series B | ||
$400m Valuation: $400m | Acquisition | ||
$5.5m | Grant | ||
$5.0m | Growth Equity VC | ||
Total Funding | €53.8m |
Recent News about Heptares Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Heptares Therapeutics
EditACQUISITION by Heptares Therapeutics Nov 2016